Physician profile
Gerald Sokol
NPI 1174590707
$61,014.13
in general payments reported to CMS, 2019-2025
51 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $2,583 · 2021: $11K · 2022: $9,782 · 2023: $1,516 · 2024: $943 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763 · Honoraria: $1,600 · Consulting Fee: $800 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.80 |
| Honoraria | $1,600.00 |
| Consulting Fee | $800.00 |
| Education | $305.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48,114.53 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $2,532.45 | 2022-2023 | |
| Alcresta Therapeutics, INC. | $1,600.00 | 2025 | Relizorb |
| Regeneron Healthcare Solutions, INC. | $1,392.67 | 2022-2023 | Libtayo |
| Rigel Pharmaceuticals, INC. | $1,014.06 | 2020-2024 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $940.74 | 2022-2024 | |
| Glaxosmithkline, LLC. | $555.33 | 2019-2022 | |
| Daiichi Sankyo INC. | $363.21 | 2022-2024 | Enhertu |
| Janssen Biotech, INC. | $341.28 | 2019-2025 | Erleada, Carvykti |
| Merck Sharp & Dohme LLC | $308.69 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $271.76 | 2019-2024 | |
| Lilly USA, LLC | $270.90 | 2019-2023 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $246.31 | 2019-2022 | |
| Pfizer INC. | $222.95 | 2019-2025 | |
| Beigene USA, INC. | $200.60 | 2021-2024 | Brukinsa |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Sokol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.